Consideration on the Research and Development of Anti-tumor Bispecific Antibody Drugs.
10.3779/j.issn.1009-3419.2022.101.43
- Author:
Yuanyuan SONG
1
;
Ling TANG
1
;
Lin XIA
1
;
Xin TONG
1
;
Zhimin YANG
1
Author Information
1. Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China.
- Publication Type:Journal Article
- Keywords:
Bispecific antibody;
Clinical research;
Research progress
- MeSH:
Antibodies, Bispecific/therapeutic use*;
Antineoplastic Agents;
DNA, Recombinant;
Epitopes;
Humans;
Immune Checkpoint Inhibitors;
Immunotherapy;
Ligands;
Lung Neoplasms/drug therapy*;
Neoplasms;
Research
- From:
Chinese Journal of Lung Cancer
2022;25(9):684-688
- CountryChina
- Language:Chinese
-
Abstract:
The drugs of programmed cell death 1 and its ligand 1 immune checkpoint inhibitors have ushered in a new era of anti-tumor immunotherapy, which has shown outstanding efficacy in some tumors, such as Hodgkin lymphoma, but there is still low response rate in some kinds of tumors. In recent years, bispecific antibodies prepared by cell fusion, recombinant DNA, protein engineering and other technologies can specifically bind two antigens or epitopes at the same time or successively, play a synergistic role in tumor treatment, can effectively inhibit tumor immune escape, and improve the effect of anti-tumor treatment has become a hot spot in tumor research. This paper will summarize the clinical research and development of bispecific antibodies, to provide reference for the industry.
.
